New combo therapy shows promise for tough prostate cancer
Disease control
Ongoing
This study tests a combination of hormone therapy, chemotherapy (docetaxel), and an immunotherapy drug (nivolumab) in 60 men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively.…
Phase: PHASE2 • Sponsor: Xiao X. Wei, MD • Aim: Disease control
Last updated May 04, 2026 16:21 UTC